StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
445680.KQ$92900.00-5.09%
Fair $92900.00+0.0%

445680.KQ

Curiox Biosystems Co., Ltd

Unknown / UnknownKOSDAQ

$92900.00

-4600.00 (-5.09%)

Fairly Valued+0.0%Fair Value $92900.00Fund rank 32/100 · Data gapFallback financials|
SA 18/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-10.0B · quality 78.7/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 44/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

18/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -51.5%, below the 5% threshold
Thesis & Journal · 445680.KQLocal privado en este navegador · Curiox Biosystems Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.59T

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-51.5%

↓

Gross Margin

41.5%

↑

Debt/Equity

0.05

↓
52-Week Range$92900
$27500$149200

TradingView lightweight chart

445680.KQ price, volumen y niveles de valoración

Último $85,800Periodo +395.1%
Fair value: $92,900

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-10.7%

FCF CAGR

—

FCF margin

-218.3%

FCF / Net income

0.41x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $5.15B · net income $-27.18B · FCF $-11.25B

2022-FY → 2025-FY

Gross margin

41.5%-23.9% pts

Operating margin

-238.7%-80.9% pts

Net margin

-527.5%-368.7% pts

FCF margin

-218.3%-70.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$5.15B$5.15B$4.59B$6.79B$7.24B
Net Income$-27.18B$-27.18B$-8.09B$-10.04B$-11.49B
EBITDA$-23.27B$-23.27B$-4.72B$-8.23B$-6.92B
EPS-1645.00-1645.00-706.00-351.00-1620.00
Gross Margin41.5%41.5%55.8%56.4%65.4%
Operating Margin-238.7%-238.7%-291.6%-155.5%-157.8%
Net Margin-527.5%-527.5%-176.3%-147.9%-158.8%
Balance Sheet
Debt/Equity0.050.050.170.020.01
Cash Flow
Free Cash Flow$-11.25B$-11.25B$-9.96B$-8.38B$-10.73B
Returns
ROE-51.5%-51.5%-16.6%-19.0%-26.2%
Valuation
P/B29.0729.074.6326.91—
Growth & Yield
Revenue Growth12.3%12.3%-32.4%-6.2%—
EPS Growth-133.0%-133.0%-101.1%78.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +205.3%

Total return

+205.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-706.00 → -1645.00

Residual

+205.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+205.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.